Specific Inhibitor of Skp2-Mediated p27 Degradation

First-in-class Specific Inhibitor of Skp2-Mediated p27 Degradation

Novel microtubule-destabilizing agent, exerting potent antitumor activity against esophageal squamous cell carcinoma

Novel microtubule-destabilizing agent, exerting potent antitumor activity against esophageal squamous cell carcinoma

Full agonist of GABAA receptors containing α2 and α3 subunits, and partial agonist of α1 and α5 subunits.

Novel nonpeptide AT1 receptor antagonist, acting as a modulator on RAAS and KKS activation during COVID-19

Potential synthetic lethal lead, targeting E-cadherin-deficient cells

Novel Potent Dual inhibitor of SLK (STE20-like kinase) and STK10 (serine/threonine kinase 10)

Novel highly selective and potent κ opioid agonist (κ, Ki = 0.47 nM, κ/μ = 682, κ/δ = 283)

Novel potent SphK2-selective inhibitor (Ki = 89 nM, 73-fold SphK2-selective) with validated in vivo activity

Novel SphK2-selective inhibitor with improved half-life to 8 h in mice

Novel selective SphK1 inhibitor

Novel SphK2-selective inhibitor

Novel efflux pump inhibitor (EPI)

Novel efflux pump inhibitor (EPI)

Potent, orally-active agonist of the ghrelin/growth hormone secretagogue receptor (GHSR) and growth hormone secretagogue

Novel Potent, Cell-Permeable, Conformationally Constrained Second Mitochondria Derived Activator of Caspase (Smac) Mimetic

Non-peptidic Smac mimetic, binding to XIAP, cIAP-1 and cIAP-2 proteins with higher affinities in cell growth inhibition in the MDA-MB-231 cell line

Novel potent and selective inhibitor of galactokinase (GALK1)

Novel inhibitor of IL-1

Proapoptotic and anti-inflammatory agent, inducing apoptosis by inhibiting apoptosis proteins (IAPs)

Novel activator of PP1, inducing HIV-1 transcription, reactivation of latent HIV-1 in chronically infected cells, and CDK9 phosphorylation